The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in the US, and it is expected to be the second leading cause of cancer deaths by 2030. The lack of effective early screening tests and alarming symptoms with early undetectable micro-metastasis at the time of presen...
Main Authors: | Marwa Elsayed, Maen Abdelrahim |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/9/4/389 |
Similar Items
-
Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma
by: Gitika Thakur, et al.
Published: (2021-02-01) -
Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
by: Natalia Michalak, et al.
Published: (2023-06-01) -
Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
by: Jannat Pervin, et al.
Published: (2023-10-01) -
Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma
by: Chengru Yang, et al.
Published: (2024-01-01) -
Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma
by: Vida Karimnia, et al.
Published: (2021-08-01)